408 related articles for article (PubMed ID: 2403834)
1. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
2. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer.
Tormey DC; Gray R; Taylor SG; Knuiman M; Olson JE; Cummings FJ
NCI Monogr; 1986; (1):75-80. PubMed ID: 3534593
[TBL] [Abstract][Full Text] [Related]
3. Six-year results of the Eastern Cooperative Oncology Group trial of observation versus CMFP versus CMFPT in postmenopausal patients with node-positive breast cancer.
Taylor SG; Knuiman MW; Sleeper LA; Olson JE; Tormey DC; Gilchrist KW; Falkson G; Rosenthal SN; Carbone PP; Cummings FJ
J Clin Oncol; 1989 Jul; 7(7):879-89. PubMed ID: 2661734
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trial of 12 cycles of CMFPT followed by observation or continuous tamoxifen versus four cycles of CMFPT in postmenopausal women with breast cancer: an Eastern Cooperative Oncology Group phase III study.
Falkson HC; Gray R; Wolberg WH; Gillchrist KW; Harris JE; Tormey DC; Falkson G
J Clin Oncol; 1990 Apr; 8(4):599-607. PubMed ID: 2179477
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Abeloff MD; Roseman DL; Gilchrist KW; Barylak EJ; Stott P; Falkson G
J Clin Oncol; 1992 Dec; 10(12):1848-56. PubMed ID: 1453199
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
Goldhirsch A; Gelber R
NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
[TBL] [Abstract][Full Text] [Related]
8. The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.
Castiglione-Gertsch M; Johnsen C; Goldhirsch A; Gelber RD; Rudenstam CM; Collins J; Lindtner J; Hacking A; Cortes-Funes H; Forbes J
Ann Oncol; 1994 Oct; 5(8):717-24. PubMed ID: 7826904
[TBL] [Abstract][Full Text] [Related]
9. The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.
Marini G; Murray S; Goldhirsch A; Gelber RD; Castiglione-Gertsch M; Price KN; Tattersall MH; Rudenstam CM; Collins J; Lindtner J; Cavalli F; Cortés-Funes H; Gudgeon A; Forbes JF; Galligioni E; Coates AS; Senn HJ
Ann Oncol; 1996 Mar; 7(3):245-50. PubMed ID: 8740787
[TBL] [Abstract][Full Text] [Related]
10. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial.
Tormey DC; Gelman R; Band PR; Sears M; Rosenthal SN; DeWys W; Perlia C; Rice MA
Cancer; 1982 Oct; 50(7):1235-44. PubMed ID: 7049347
[TBL] [Abstract][Full Text] [Related]
11. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
12. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy.
Fowble B; Gray R; Gilchrist K; Goodman RL; Taylor S; Tormey DC
J Clin Oncol; 1988 Jul; 6(7):1107-17. PubMed ID: 3292711
[TBL] [Abstract][Full Text] [Related]
13. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Zambetti M; Veronesi U
Breast Cancer Res Treat; 1985; 5(2):95-115. PubMed ID: 3839424
[TBL] [Abstract][Full Text] [Related]
14. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial.
International Breast Cancer Study Group (IBCSG)
J Natl Cancer Inst; 2002 Jul; 94(14):1054-65. PubMed ID: 12122096
[TBL] [Abstract][Full Text] [Related]
15. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
International Breast Cancer Study Group
J Clin Oncol; 1997 Apr; 15(4):1385-94. PubMed ID: 9193330
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in early breast cancer.
Ejlertsen B
Dan Med J; 2016 May; 63(5):. PubMed ID: 27127018
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M; Jonat W; Abel U; Hilfrich J; Caffier H; Kreienberg R; Trams G; Brunnert K; Schermann J; Kleine W
J Clin Oncol; 1993 Mar; 11(3):454-60. PubMed ID: 8445420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
